Subjective Global Assessment in chronic kidney disease: A review

2004 ◽  
Vol 14 (4) ◽  
pp. 191-200 ◽  
Author(s):  
Alison L. Steiber ◽  
Kamyar Kalantar-Zadeh ◽  
Donna Secker ◽  
Maureen McCarthy ◽  
Ashwini Sehgal ◽  
...  
2004 ◽  
Vol 14 (4) ◽  
pp. 191-200 ◽  
Author(s):  
Alison L. Steiber ◽  
Kamyar Kalantar-Zadeh ◽  
Donna Secker ◽  
Maureen McCarthy ◽  
Ashwini Sehgal ◽  
...  

2017 ◽  
Vol 4 (2) ◽  
pp. 481
Author(s):  
Arvind Gupta ◽  
Anubha Srivastava ◽  
Upma Narain ◽  
Parag Saraswat

Background: Malnutrition is an important risk factor in patients with chronic kidney disease and in those undergoing maintenance dialysis. Subjective global assessment is a reliable method to evaluate malnutrition in these patients. This study aims to evaluate malnutrition in patients of chronic kidney disease using subjective global assesment score.Methods: A cross sectional study was conducted at SRN Hospital, Allahabad, Uttar Pradesh, India on patients attending Nephrology Unit from July 2014 to May 2015.The nutritional status of 100 patients was evaluated using dietary recall, anthropometry, biochemical parameter and subjective global assessment. There were 67 males and 23 females. Their mean age was 46.8 years. Subjective global assessment was done using 7 variables derived from medical history and physical examination. Each variable was scored from 1-5 depending on the severity. The subjective global assessment score was correlated with the standard methods.Results: Out of 100 patients 29% were mildly malnourished, 64% were moderately malnourished and 7% were severely malnourished. The age, triceps thickness, serum urea and cholesterol were correlated with the malnutrition score (r value 0.2, -0.3, 0.2, 0.4 respectively and p-value 0.3, 0.002, 0.007, 0.001 respectively). It was found that the serum albumin (r value -0.21, p-value 0.42) level did not correlate well with the subjective global assessment.Conclusions: The subjective global assessment can be used reliably to assess the malnutrition in the patients of chronic kidney disease and hence useful in prognostication of disease and is a convenient bedside tool, operable even with  paramedics.


2012 ◽  
Vol 31 (2) ◽  
pp. A27
Author(s):  
Marion Schneider Meireles ◽  
Ana Catarina ◽  
de Castro ◽  
Mariana Leister Rocha ◽  
Maria Ayako Kamimura ◽  
...  

Author(s):  
Mozhgan Taebi ◽  
John R. Cutcliffe ◽  
Azar Jafari ◽  
Yasaman Hatef Matbue ◽  
Masoumeh Bagheri Nesami ◽  
...  

Introduction: Hemodialysis as a common and vital method of treatment in kidney patients, despite maintaining the survival of patients can be a source of stress for them. Material and Methods: In this descriptive-correlational study, which was conducted in 2019, 97 patients with chronic kidney disease under hemodialysis in the dialysis center of Imam Reza Amol Hospital entered the study with census method. Data were collected using demographic information form and The Nurseschr('39') Global Assessment of Suicide Risk (NGASR) instrument. Results: The mean age of the patients in the present study was 53.2 years (SD = 13.18, CI95%: 50.54-55.85). According to the findings of this study, the mean risk of suicide in hemodialysis patients was 19.32. Conclusion: According to the results of this study, the risk of suicide in hemodialysis patients was very high.


2020 ◽  
Vol 5 (4) ◽  
pp. 160-163
Author(s):  
Eingun James Song

Background: Chronic kidney disease is a relative contraindication for conventional systemic therapy in patients with psoriasis. Although biologic agents may be suitable in these patients due to their elimination via endogenous metabolism and protein degradation, no dedicated studies have evaluated the safety of biologics in patients with psoriasis and chronic kidney disease. Tildrakizumab—an anti-interleukin-23p19 monoclonal antibody—is approved for treatment of moderate-to-severe plaque psoriasis. Objective: To evaluate efficacy and safety of tildrakizumab in a 56-year-old woman with moderate-to-severe plaque psoriasis and comorbid immunoglobulin A nephropathy. Methods: Subcutaneous tildrakizumab 100 mg was administered at weeks 0, 4, 20, 33, and 48. Assessments included body surface area affected, physician’s global assessment score, and laboratory assessments. Results: At initial presentation, patient had predominantly plaque-type psoriasis involving 5% body surface area with a static physician’s global assessment score of 3. Patient failed an adequate trial of ultrapotent topical steroids. Baseline laboratory tests confirmed renal impairment with blood creatinine level of 2.0 mg/dL and an estimated glomerular filtration rate of 27.0 mL/min/1.73 m2. Administration of subcutaneous tildrakizumab 100 mg led to near-complete skin clearance by week 33, with a durable response to week 48. No treatment-related adverse events were reported through 48 weeks. Metabolic and hematological parameters remained grossly unchanged. Conclusion: Tildrakizumab was well tolerated and effective for treatment of moderate-to-severe plaque psoriasis in a patient with comorbid immunoglobulin A nephropathy.


Sign in / Sign up

Export Citation Format

Share Document